NASDAQ:KDNY

Chinook Therapeutics (KDNY) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $40.29
▼
$40.51
50-Day Range: $38.66
▼
$40.39
52-Week Range: $18.34
▼
$40.51

Volume: 4.92 million shs
Average Volume: 1.19 million shs
Market Capitalization: $2.90 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.14

Chinook Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.23 Rating Score
Upside/Downside: 5.6% Downside
$38.14 Price Target
Short Interest: N/A
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$45,587 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.30) to ($3.50) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.83 out of 5 stars

Medical Sector

963rd out of 971 stocks

Biotechnology Industry

12th out of 14 stocks

1.1

Analyst's Opinion

Consensus Rating
Chinook Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.23, and is based on 3 buy ratings, 10 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $38.14, Chinook Therapeutics has a forecasted downside of 5.6% from its current price of $40.39.
Amount of Analyst Coverage
Chinook Therapeutics has only been the subject of 2 research reports in the past 90 days.

N/A

Short Interest

Short Interest
There is no current short interest data available for KDNY.

0.0

Dividend Strength

Dividend Yield
Chinook Therapeutics does not currently pay a dividend.
Dividend Growth
Chinook Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for KDNY.

0.0

News and Social Media Coverage

MarketBeat Follows
Only 1 people have added Chinook Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Chinook Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $45,587.00 in company stock.
Percentage Held by Insiders
16.79% of the stock of Chinook Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
95.15% of the stock of Chinook Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Chinook Therapeutics are expected to decrease in the coming year, from ($3.30) to ($3.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Chinook Therapeutics is -11.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Chinook Therapeutics has a P/B Ratio of 5.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Chinook Therapeutics (NASDAQ:KDNY) Stock

Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington. As of August 11, 2023, Chinook Therapeutics, Inc. operates as a subsidiary of Novartis AG.

August 8, 2023 | msn.com

Wedbush Downgrades Chinook Therapeutics (KDNY)

August 2, 2023 | uk.finance.yahoo.com

Chinook Therapeutics, Inc. (KDNY)

October 1, 2023 | Legacy Research (Ad)

Watch SHOCKING Footage of AI Facility with Ties to Elon Musk

I recently traveled more than 3,000 miles and shot this video outside what could end up being Elon Musk’s biggest secret. Most people don’t know about this facility, but it could be the most important AI project in the world. What’s happening inside these walls is so important that our government has declared it a matter of national security.

August 1, 2023 | markets.businessinsider.com

Expert Ratings for Chinook Therapeutics

August 1, 2023 | msn.com

Wells Fargo Downgrades Chinook Therapeutics (KDNY)

July 25, 2023 | markets.businessinsider.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates KDNY, NETI, TALS, QUOT

July 16, 2023 | fool.com

Chinook Therapeutics (NASDAQ: KDNY)

June 21, 2023 | seekingalpha.com

Chinook: Surprising Acquisition By Novartis, Deal Should Go Through

October 1, 2023 | Goldco (Ad)

Ben Stein FREE Report: How Americans Are RUINING Retirement

There’s a new report just out from famed author, actor and economist Ben Stein. In this FREE REPORT, Ben reveals the lessons he learned from his late father and economist Herbert Stein. Discover how everyday Americans are currently ruining their retirements, and how YOU can save yours!

June 17, 2023 | finance.yahoo.com

Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress

June 16, 2023 | benzinga.com

Moore Kuehn Encourages NETI, SURF, KDNY, and NEX Investors to Contact Law Firm

June 14, 2023 | businesswire.com

CHINOOK THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Chinook ...

June 13, 2023 | barrons.com

KDNY Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Chinook Therapeutics, Inc. Is Fair to Shareholders

June 13, 2023 | reuters.com

Novartis buys Chinook for $3.5 bln in race to treat rare kidney disease

June 13, 2023 | markets.businessinsider.com

Why Are Chinook Therapeutics Shares Trading Higher Today

June 12, 2023 | markets.businessinsider.com

What 6 Analyst Ratings Have To Say About Chinook Therapeutics

June 12, 2023 | finance.yahoo.com

Chinook Therapeutics to Present Updated Data from Zigakibart (BION-1301) Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) at the 60th European Renal Association (ERA) Congress

June 12, 2023 | seekingalpha.com

Novartis Buys Chinook: M&A To Drive Future Growth

June 12, 2023 | investorplace.com

Why Is Chinook Therapeutics (KDNY) Stock Up 58% Today?

June 8, 2023 | markets.businessinsider.com

Chinook Shareholder Action Reminder

May 23, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Tandem Diabetes Care (TNDM), Chinook Therapeutics (KDNY) and Zoetis (ZTS)

May 21, 2023 | benzinga.com

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Chinook Therapeutics, Inc. - KDNY

May 21, 2023 | benzinga.com

Chinook Shareholder Notice

May 19, 2023 | seekingalpha.com

Chinook Therapeutics: Travere's Pain Is Chinook's Gain

May 19, 2023 | benzinga.com

Chinook Investor Alert

May 18, 2023 | benzinga.com

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

May 17, 2023 | benzinga.com

INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Chinook Therapeutics, Inc. (KDNY) on Behalf of Investors

See More Headlines

Receive KDNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Chinook Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KDNY Company Calendar

Last Earnings: 8/07/2023
Today: 10/01/2023
Next Earnings (Estimated): 11/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KDNY
CUSIP: N/A
CIK: 1435049
Web: chinooktx.com
Phone: (206) 485-7241
Fax: N/A
Employees: 214
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $38.14
High Stock Price Forecast: $43.00
Low Stock Price Forecast: $32.00
Forecasted Upside/Downside: -5.6%
Consensus Rating: Hold
Rating Score (0-4): 2.23
Research Coverage: 13 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.52)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-187,870,000.00
Net Margins: -4,199.93%
Pretax Margin: -4,115.56%
Return on Equity: -58.28%
Return on Assets: -44.72%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.82
Quick Ratio: 5.82

Sales & Book Value

Annual Sales: $6.13 million
Price / Sales: 473.15
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.91 per share
Price / Book: 5.85

Miscellaneous

Outstanding Shares: 71,810,000
Free Float: 59,749,000
Market Cap: $2.90 billion
Optionable: Optionable
Beta: 0.34

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Eric L. Dobmeier J.D. (Age 54)
Pres, CEO & Director
Comp: $972.19k

Mr. Tom Frohlich (Age 47)
Chief Operating Officer
Comp: $627.44k

Mr. Andrew James King D.V.M. (Age 43)
Ph.D., Chief Scientific Officer
Comp: $651.48k

Mr. Eric H. Bjerkholt M.B.A. (Age 63)
Chief Financial Officer

Ms. Sukhi Thethy
Sr. VP of Fin. & Accounting

Ms. Noopur Batsha Liffick
Sr. VP of Investor Relations & Corp. Communications

Mr. Kirk D. Schumacher J.D.
Sr. VP & Gen. Counsel

Ms. Jodi Jamieson
Sr. VP of HR

Dr. Alan Glicklich M.D. (Age 60)
Exec. Officer

Ms. Delphine Imbert Ph.D.
Sr. VP of CMC & Technical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KDNY Stock - Frequently Asked Questions

Should I buy or sell Chinook Therapeutics stock right now?: 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Chinook Therapeutics in the last year. There are currently 10 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" KDNY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KDNY, but not buy additional shares or sell existing shares.
View KDNY analyst ratings or view top-rated stocks.
What is Chinook Therapeutics' stock price forecast for 2023?: 13 brokerages have issued twelve-month target prices for Chinook Therapeutics' stock. Their KDNY share price forecasts range from $32.00 to $43.00. On average, they predict the company's stock price to reach $38.14 in the next year. This suggests that the stock has a possible downside of 5.6%.
View analysts price targets for KDNY or view top-rated stocks among Wall Street analysts.
When is Chinook Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our KDNY earnings forecast.
How were Chinook Therapeutics' earnings last quarter?: Chinook Therapeutics, Inc. (NASDAQ:KDNY) released its quarterly earnings results on Monday, August, 7th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.81) by $0.13. The business earned $1.01 million during the quarter, compared to analyst estimates of $0.47 million. Chinook Therapeutics had a negative trailing twelve-month return on equity of 58.28% and a negative net margin of 4,199.93%.
What ETFs hold Chinook Therapeutics' stock?: ETFs with the largest weight of Chinook Therapeutics (NASDAQ:KDNY) stock in their portfolio include IQ Merger Arbitrage ETF (MNA), AltShares Merger Arbitrage ETF (ARB), ProShares Merger ETF (MRGR), First Trust Merger Arbitrage ETF (MARB), ALPS Medical Breakthroughs ETF (SBIO), SPDR S&P Biotech ETF (XBI), Simplify Propel Opportunities ETF (SURI) and Direxion Daily S&P Biotech Bull 3x Shares (LABU).

What other stocks do shareholders of Chinook Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Chinook Therapeutics investors own include BioSyent (RX) and Continental Resources (CLR).
What is Chinook Therapeutics' stock symbol?: Chinook Therapeutics trades on the NASDAQ under the ticker symbol "KDNY."
What is Chinook Therapeutics' stock price today?: One share of KDNY stock can currently be purchased for approximately $40.39.
How much money does Chinook Therapeutics make?: Chinook Therapeutics (NASDAQ:KDNY) has a market capitalization of $2.90 billion and generates $6.13 million in revenue each year. The company earns $-187,870,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.
How many employees does Chinook Therapeutics have?: The company employs 214 workers across the globe.
How can I contact Chinook Therapeutics?: Chinook Therapeutics' mailing address is 740 HEINZ AVENUE, BERKELEY CA, 94710. The official website for the company is chinooktx.com. The company can be reached via phone at (206) 485-7241 or via email at investors@aduro.com.

This page (NASDAQ:KDNY) was last updated on 10/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Chinook Therapeutics (KDNY) Stock Forecast, Price & News

Chinook Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Short Interest

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Chinook Therapeutics (NASDAQ:KDNY) Stock

KDNY Stock News Headlines

KDNY Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KDNY Stock - Frequently Asked Questions

Overall MarketRank^™